Visus Therapeutics, Inc.’s Post

🎉 Exciting Announcement! 🎉 The UNC Eshelman School of Pharmacy's groundbreaking innovation engine is evolving. Ten years after Fred Eshelman’s transformative $100M gift — the largest individual commitment in the University’s history — launched the Eshelman Institute for Innovation, we’re rebranding! 🚀 Eshelman Innovation has a new look to go with its proven process for turning great ideas into healthcare products and services that improve lives in North Carolina and throughout the world.  Our Therapeutics Accelerator has driven novel solutions to unmet needs in oncology, neuroscience and infectious diseases. Our Venture Studio nurtures game-changing digital health startups to combat harms caused by opioid use disorder, food insecurity and more. At Eshelman Innovation, when we encounter a healthcare problem, we don’t back away. We charge toward it. The blueprint for the “Eshelman Way” grew out of lessons learned on the road to READDI’s success. Find out how: https://lnkd.in/dqPnrEZj And watch the video: https://lnkd.in/enJHcUnG #UNC #READDI #ResearchTriangleRegion #Pharmacy #BioTechnology

📣 Noctrix Health Raises $40M in Series C Financing! The round was led by Sectoral Asset Management and included investors such as Resmed, Angelini Ventures, Asahi Kasei Corporation, OrbiMed and Treo Ventures. Noctrix Health was incorporated in 2018 with a mission to make clinically validated wearable therapeutics as an alternative to pharmaceuticals for the management of chronic neurological disorders. View the HealthTech Alpha Venture Flashcard to gain more insight on Noctix Health- funding, partnerships and more. #digitalhealthcare #digitalhealth #digitalhealthinnovation #neurologicalhealth #neurologicaldisorders #healthcareinnovation

🔌 Innovating at the Intersection of Medicine and Technology ⚙️ In the ever-evolving field of medical devices, the integration of electrical systems is unlocking new possibilities for patient care. This Tech Talk between Holly Scott of the Mullings Group and David N Constantine of Juniper Biomedical, is a great reminder of how far the industry has come in improving patient outcomes, and the potential that still lies ahead. In the spirit of Copetition (Thanks Holly Scott) we help companies bring their innovative medical devices to life by combining advanced COMSOL modeling with rapid prototyping and rigorous testing. Whether it’s refining a concept or navigating the complexities of electrical design, we’re here to support every step of your device technology development journey. If you’re working on the next breakthrough in medical technology, let’s connect and explore how we can collaborate. #MedicalDevices #Neuromodulation #Electroceuticals #Bioelectronics #TechnologyDevelopment #COMSOL

𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐒𝐭𝐫𝐨𝐤𝐞 𝐂𝐚𝐫𝐞: 𝐁𝐚𝐬𝐤𝐢𝐧𝐠 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $𝟓𝟓𝐌 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 Basking Biosciences Basking Biosciences Inc, a pioneer in stroke treatment, has closed a $55 million financing round to accelerate the development of BB-031, a groundbreaking reversible thrombolytic therapy for ischemic stroke. Led by ARCH Venture Partners, this funding will drive Basking's mission to enhance patient outcomes. BB-031, a first-in-class RNA aptamer targeting von Willebrand Factor, demonstrated safety and tolerability in Phase 1, with promising results. The RAISE trial, a Phase 2 proof-of-concept study for acute ischemic stroke, is set to commence in 2024. "We're driven by the urgent need for innovative stroke treatments," says Richard Shea Rich Shea, CEO of Basking. The company will also advance BB-025, a rapid-acting reversal oligonucleotide, through a Phase 1 clinical program. Basking's vision, guided by two decades of research led by Dr. Bruce Sullenger, is poised to revolutionize stroke care. Steven Gillis, Ph.D. Steve Gillis, of ARCH Venture Partners, will serve as Chairman of Basking’s Board. #BB031 #RAISEtrial #InvestmentNews #StrokeCare #MedicalAdvancements #BioTechFinance #PatientOutcomes #RNAaptamers #ThrombolyticTherapy

Come join Shaheen E Lakhan, MD, PhD, FAAN and I tomorrow at the Future Health: Best Practices for Advancing Care conference. We are excited to be invited back again this year to share all about the latest advances in prescription digital therapeutics with such a prestigious group! #healthcare #digitalmedicine #digitaltherapeutics #AI

Two more biotechs will go public Friday morning as Alto Neuroscience and Fractyl Health build on the momentum created by CG Oncology and ArriVent Biopharma’s Nasdaq listings last week. California drugmaker Alto Neuroscience raised about $128.6 million in its upsized NYSE listing, as the mid-stage #CNS #biotech priced at $16 apiece $ANRO, the high end of the range it proposed earlier this week. Fractyl Health, meanwhile, landed on the Nasdaq with $110 million in proceeds by pricing at $15 a share $GUTS, the mid-point of the range it disclosed on Monday. The listings come as investors and private life sciences startups look for greener pastures in 2024 after two years of icy conditions in the public markets and belt-tightening for venture-backed drug development. ... #IPO #financing #financingoptions #fundraising #lifesciences #lifescience #biotech #biotechnology #healthcare #regenerativemedicine #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #pharmaceutical #pharma #publicmarkets #defrosting #positivesignals Amit Etkin Harith Rajagopalan ALPHAWAVE VENTURES Apeiron Investment Group #diabetes #obesity Peter Thiel Mithril Capital Management LLC General Catalyst Bessemer Venture Partners Domain Associates CVF Capital Partners #doubleheader #drugdevelopment

Grateful as our "Fractional C Suite" offering announced last month has been well received by our clients resulting in a few engagements for oncology clinical trials. Check out our new website and blog posts for an understanding of how we can help develop superior, targeted therapies to improve patient outcomes. #fractionalcmo #fractionalcso #fractionalexpertise #clinicaldevelopment #translationalscience #computationalscience #precisionmedicine

𝐓𝐏𝐆 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 $𝟓𝟖𝟎𝐌 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐅𝐮𝐧𝐝: 𝐀 𝐌𝐚𝐣𝐨𝐫 𝐁𝐨𝐨𝐬𝐭 𝐟𝐨𝐫 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 TPG has unveiled a $580 million fund dedicated to life sciences, named TPG Life Sciences Innovations (LSI). This fund, which has already started investing in promising biotech companies, aims to support the development of novel therapeutics, digital health, medical devices, diagnostics, and tech-enabled services. 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐅𝐨𝐜𝐮𝐬: Most of the fund’s capital will go into preclinical and clinical-stage therapeutics companies. Therapeutic areas include oncology, immunology and inflammation (I&I), cardiometabolic diseases, ophthalmology, and rare diseases. 𝐊𝐞𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐆𝐨𝐚𝐥𝐬: - MBrace Therapeutics: MBrace raised $85 million in a Series B financing round led by TPG LSI, bringing its total funding to over $110 million. The funds will accelerate the clinical development of their antibody-drug conjugate (ADC) pipeline, particularly for difficult-to-treat cancers such as breast, non-small cell lung, and pancreatic cancers. - Sudo Biosciences: Sudo secured $116 million in a Series B round to advance its TYK2 inhibitors for treating multiple sclerosis and psoriasis. This funding aims to push two investigational candidates into clinical trials by 2024, addressing significant unmet needs in neuroinflammation and autoimmune diseases. - Santa Ana Bio, Inc.: An immunology startup focusing on innovative treatments in the immunology space. - Bicara Therapeutics: An oncology-focused biotech company developing novel therapeutics. 𝐀𝐛𝐨𝐮𝐭 𝐓𝐏𝐆 𝐋𝐢𝐟𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬: TPG LSI partners with companies developing disruptive science and technologies to improve outcomes for patients with significant unmet medical needs. The fund leverages TPG's extensive expertise in various therapeutic areas and aims to advance breakthrough technologies to clinical proof-of-concept. TPG has invested over $30 billion in healthcare since 2003, focusing on oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, and commercial stage medical devices.

Today is #WorldCancerDay dedicated to raising awareness about cancer and honoring those affected by the disease. It is the third and final year of the campaign 'Close the care gap', which calls on governments to take action to reduce inequities in accessing quality cancer care. Throughout this day, we are recognizing the groundbreaking medical innovations and progress by our portfolio companies in helping make cancer diagnosis and treatment more accurate >> IntraGel Therapeutics, Dio Tree, Barcode Nanotech, UB Therapeutics, Ark Surgical Ltd., MicroSteer Robotics and EMRIS Pharma. Find out more about their remarkable innovations at >> https://lnkd.in/dwHSYRMz Let's help create a future without cancer. 🇮🇱 Israeli tech, #nomatterwhat! #CancerAwareness #EarlyDetection #CloseTheCarGap